BioLife, Shire, Others Turning Regenerative Medicine Industry from Gravel Road to Paved Street

BioLife Solutions (BLFS)

The industry can be broadly called regenerative medicine, life sciences, biologics, stem cells and more.  Regardless of the name, it is ubiquitously recognized as a space that is really starting to get its legs under it.  What that leaves for investors is a significant opportunity in a burgeoning industry as there is a quickly growing field of leaders with solid upside potential that are still trending at prices that could be construed as undervalued.  Some may not look favorably on biologics and focus on Geron (NASDAQ: GERN) discontinuing its stem cell trials without giving clear thought to all the hurdles that the company faced with the very limited scope of their trial to get target patients.  Although that trial ceased, it was a ribbon-cutting-type of milestone for the industry and should be recognized as such.

Advanced Cell Technology (OTCBB: ACTC), the second company to ever receive FDA approval for stem cell-related clinical trials, has demonstrated safety using its human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) cells for the treatment of Stargardt’s macular dystrophy (SMD) and dry age-related macular degeneration (dry AMD).

Shares of Regenicin, Inc. (OTCBB: RGIN) got a lift this week as the junior biotech said that the FDA granted Orphan Status approval for its PermaDerm® product, the only tissue-engineered skin prepared from patient’s own (autologous) skin cells consisting of both epidermal and dermal layers, that is indicated for catastrophic burn patients.  Regenicin’s technology can harvest a small section of the patient’s skin and grow it in as little as one month to graft an area 100 times larger.  Being autologous, the body’s immune system tends to not reject the graft as is common with today’s porcine or cadaver skin graft treatments.  The FDA had previously designated PermaDerm® to be a biological/drug (permanent skin replacement) not a medical device (temporary skin replacement). PermaDerm® is the only skin replacement technology to receive this Biological/drug designation.

Also in the news this week, global specialty biotech Shire plc (LSE: SHP, NASDAQ: SHPGY), said that its Regenerative Medicine business, Advanced BioHealing, Inc., has entered into a lease agreement with BioMed Realty Trust, Inc.   An industry leader, the move will allow Advanced BioHealing to further expand its operational footprint and presence in the San Diego, California area, including meeting future demand for its lead product, Dermagraft®, a cryopreserved human fibroblast-derived dermal substitute, approved by the FDA for the treatment of diabetic foot ulcers.

A truly compelling company that is blossoming with the industry knows many of the others in the regenerative medicine space quite well as clients, not competition, which can increase its upside potential.  BioLife Solutions Inc. (OTCBB: BLFS) develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues.  The company has three proprietary products, HypoThermosol®, BloodStor® and CryoStor® on the market today and generating revenue through sales to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing.

The company’s clinical-grade biopreservation media products provide these organizations with superior technology across a broad range of applications ranging from traditional bone-marrow stem-cell transplants to the banking of newborn umbilical cord blood.  Hypothermic storage or freezing is used to reduce metabolism of precious biologic source material, such as cells and tissues, once they are removed from the body.

Now posting seven straight quarters of growing revenue with Q1 2012 revenue topping $830,000, the company is in the midst of expanding their corporate offices and production facility.  The expansions should be reflected in future financial reports.  As the company stated in a May 14, 2012 press release, “The additional space will be dedicated to the build-out of an additional GMP manufacturing clean room suite to support increasing demand for the Company’s biopreservation media products and also to fulfill the production obligations of a high value multi-year contract manufacturing agreement that was executed in late 2011.”

A member of the Alliance for Regenerative Medicine (ARM), BioLife Solutions is front and center with its offerings in the industry while advocating for the advancement regenerative medicine along with its peers.  The company currently works with market leader Lonza and other members of ARM.

The regenerative medicine industry is bursting with opportunities as the field is truly gaining traction and making substantial headway after years of delineating many boundaries and practices akin to the way traditional biotechnology found its footing many years earlier.  Similar to legacy-type biotechs, regenerative medicine plays carry high risk/reward characteristics, but as a reasonable hedge to the risk, BioLife Solutions has particular appeal because of its broad value to the industry as a whole.  It would seem fair to say the as the industry grows, so grows BioLife.

BioLife Solutions (BLFS) Stock Quote and News:

Disclaimer: Neither nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at


Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Stocks Mixed on Monday

Stocks Mixed on Monday(0)

The Dow Jones industrial average topped 16,000 for the first time ever Monday, while the S&P 500 briefly surpassed 1,800. The Dow retreated from the 16,000 level, but still gained 14.32 points from Friday”s all-time high close, to 15,976. The S&P 500 index dipped 6.65 points to 1,791.53. The NASDAQ fell 36.90 points to 3,949.07

Catalyst Pharmaceutical Partners Stock Chart Analysis Video

Catalyst Pharmaceutical Partners Stock Chart Analysis Video(0)

The Catalyst Pharmaceutical Partners (NASDAQ: CPRX) stock chart formed a piercing line reversal pattern on Wednesday and Thursday that was confirmed with a sharp move upwards on Friday. Technical traders will be watching support around the 200 day moving average at $1.25 on any pullback, but for the time being, the chart looks to be

EnteroMedics Stock Chart Analysis Video

EnteroMedics Stock Chart Analysis Video(0)

The EnteroMedics (NASDAQ:ETRM) chart has been making higher highs and higher lows since forming a double bottom early in the year. The chart is holding over the 50-day moving average and inching higher each day as it tries to gain momentum to make the next leg up in the channel. EnteroMedics is a medical device

NXT-ID Authentication Using Face and Voice Recognition

NXT-ID Authentication Using Face and Voice Recognition(0)

There’s a Wocket in My Pocket! may soon not just be a sentence from the mouths of children after reading the rhyming book by Dr. Seuss. There was plenty of made-up ridiculousness in the iconic book, such as a bofa on the sofa, but there is nothing fictitious about the Wocket, a next-generation payment and

Dow Not Tired of Making New Record Highs

Dow Not Tired of Making New Record Highs(0)

The Dow Jones Industrials will have to wait till at least next week to mount the lofty heights of 16,000 points, but both the Dow and the S&P did end the day at record highs. The Dow Jones Industrials was up 85.48 points from yesterday”s all-time high, to close at 15,961.70 The S&P 500 index

read more

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.